growth%20hormone%20deficiency%20(pediatric)
GROWTH HORMONE DEFICIENCY (PEDIATRIC)
Growth hormone deficiency is a congenital or an acquired growth hormone axis disruption in the higher brain, hypothalamus or pituitary which results in short stature.
It may occur at any age.
Short stature is often the only feature present in patients with growth hormone deficiency and other causes of subnormal growth rate.
Etiology may be congenital conditions (eg defective pituitary development that leads to pituitary aplasia, empty sella, encephalocele, midline defects) or acquired conditions (eg tumors of the hypothalamic-pituitary region, cranial irradiation, infiltrative disease).

Monitoring

Prescribed End Points

  • IGF-I in normal range for age and sex
    • Increase dose if IGF-I is low and decrease dose if IGF-I is above normal range
  • Improvement in blood lipid profile, body composition (change in lipolysis and increase in bone density) and waist-hip ratio
  • Increased muscle strength and exercise performance
  • Reduction in cardiovascular risk factors

Patient Monitoring

  • Close follow-up care with an endocrinologist is recommended to monitor the child’s growth, assessment of potential adverse effects, and to adjust the dose of growth hormone (GH) therapy
  • Initial follow-up should be every month; thereafter, visits may be less frequent but should be at least 2x/year
  • Children on growth hormone (GH) therapy should be evaluated every 3-6 months, with increases in height and height velocity as the most important indicators of response
  • Monitor thyroid function every 6 months
  • Bone age, HbA1c levels, and adrenal function should also be assessed regularly
  • Monitor patients for hyperglycemia because growth hormone (GH) may reduce insulin sensitivity; patients with diabetes mellitus (DM) may need to adjust their insulin during treatment
    • Serum IGF-1 and IGFBP-3 levels should be obtained annually to effectively monitor treatment adherence & response
    • Dose should be reduced if serum IGF-1 levels increase above the normal range
  • Funduscopic examination is recommended at the start of therapy and periodically during the course of treatment
  • Growth hormone (GH) treatment is meant to be a replacement therapy and can only be expected to make short children grow at a normal growth rate
  • Most children treated with growth hormone (GH) replacement reach a normal adult height
    • Child’s growth usually increases most during the 1st years, with an average increase of 8-10 cm/year
    • Growth rate slows down over the next several years
  • Re-evaluation should be done once patient completed
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, Yesterday

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
04 Jan 2019
Obstructive sleep apnoea may increase the risk of male-pattern baldness in men with a family history of hair loss, and this association appears to be mediated by low serum transferrin saturation levels related to hypoxia, a study suggests.
Elvira Manzano, 2 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.